What is Praxis Precision Medicines Inc (PRAX) stock price today?

Praxis Precision Medicines Inc (PRAX) currently trades at $323.19 per share. The stock has a market capitalization of $9.00B and a P/E ratio of —x.

Is PRAX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Praxis Precision Medicines Inc has a Smart Value Score of 33/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 3.51.

What is Praxis Precision Medicines Inc's revenue and earnings?

Praxis Precision Medicines Inc has trailing twelve-month (TTM) revenue of $7.46M with profit margins of 0.00%. Earnings per share (EPS) is $-13.47.

Is Praxis Precision Medicines Inc financially healthy?

Praxis Precision Medicines Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 3.51 places it in the safe zone.

PRAX

Praxis Precision Medicines Inc

NASDAQ: PRAX · HEALTHCARE · BIOTECHNOLOGY

$323.19

+0.39% today

Updated 2026-04-29

Market cap

$9.00B

P/E ratio

—

P/S ratio

953.14x

EPS (TTM)

$-13.47

Dividend yield

—

52W range

$35 – $356

Volume

0.4M

Market cap

$9.00B

P/E ratio

—

P/S ratio

953.14x

EPS (TTM)

$-13.47

Dividend yield

—

52W range

$35 – $356

Volume

0.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.3

Growth

7.3

Quality

B+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

3.5

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$634.24

+96.24%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy12 Buy1 Hold1 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 3.51 — safe zone

+ Revenue growth 1,349.00% QoQ

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-77.26M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$1.46M	$2.45M	$8.55M	$0.00	$7.46M
Net income	$-213.07M	$-123.28M	$-182.82M	$-303.27M	$-88.91M
EPS	—	—	—	—	$-13.47
Free cash flow	$-185.49M	$-111.19M	$-131.76M	$-249.12M	$-77.26M
Profit margin	-14,554.10%	-5,037.88%	-2,137.48%	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-02-06	KINDLER, JEFFREY B	Buy	224	—
2026-02-06	KINDLER, JEFFREY B	Buy	688	—
2026-02-06	KINDLER, JEFFREY B	Buy	478	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PRAX	$9.00B	33	6.3	3.0	5.0	7.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Praxis Precision Medicines Inc trades at $323.19. Our Smart Value Score of 33/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.51, it sits in the safe zone. TTM revenue stands at $7.46M.

Frequently asked questions

What is Praxis Precision Medicines Inc's stock price?

Praxis Precision Medicines Inc (PRAX) trades at $323.19.

Is Praxis Precision Medicines Inc overvalued?

Smart Value Score 33/100 (Grade F, Strong Sell).

What is the price target of Praxis Precision Medicines Inc (PRAX)?

The analyst target price is $634.24, representing +96.2% upside from the current price of $323.19.

What is Praxis Precision Medicines Inc's revenue?

TTM revenue is $7.46M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

3.51 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio953.14x

ROE-45.80%

Beta2.97

50D MA$318.74

200D MA$199.97

Shares out0.03B

Float0.03B

Short ratio—

Avg volume0.4M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

PRAX vs LLY →PRAX vs JNJ →PRAX vs ABBV →Stock screener →